Novartis Wins Bid to Shut Down MSN Challenge of Entresto Patent

MSN Laboratories Pvt. Ltd. can’t reopen disputes resolved in earlier litigation over the scope, validity, and infringement of a patent for Novartis AG’s blockbuster heart-failure drug Entresto, a federal judge ruled.

Novartis’ allegations that MSN infringed US Patent No. 8,101,659 by importing its generic version of Entresto and offering it for sale implicate the same questions about what the patent covers, whether it’s valid, and whether MSN’s copy infringes that were fully decided in a 2020 Hatch-Waxman case over generics of the drug, according to an opinion issued Wednesday in the US District Court for the District of Delaware.

Judge ...